Delivery Order SPE2DB20D9354-SPE2DB26FX7F7

The Defense Logistics Agency issued a firm fixed-price delivery order valued at $5,503.02 to DMS Pharmaceutical Group Inc. for Beyfortus 100 mg/ml syringes on October 27, 2025, with completion expected by October 28, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. The delivery order will be performed at the awardee's Park Ridge location and represents a continuation of the company's substantial pharmaceutical supply role within the Department of Defense's medical supply chain.

This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency, specifically the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded on November 13, 2025, with a $500 million ceiling and completion date of December 31, 2036. The PPV-G GEN V program represents part of a broader $30.3 billion acquisition strategy designed to ensure Department of Defense healthcare facilities worldwide have access to comprehensive pharmaceutical products including branded and generic prescription medications, biologics, and medical consumables. Through this prime vendor arrangement, DMS Pharmaceutical Group serves as a critical regional pharmaceutical supplier supporting recurring medical supply needs across the military healthcare system.